FindMyKOL

Donald Eagerton, MD

Basic profile

Strand Physician Specialists

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionMyrtle Beach, SC · SoutheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Donald Eagerton is an Endocrinology/Metabolic physician affiliated with Strand Physician Specialists. OpenAlex indexes 16 publications with 2,816 citations (h-index 10).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
16publications

Publications indexed by OpenAlex. Counts exclude supporting files.

2,816citations

Citations across these publications.

10h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
64companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

64 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Moderna
    Program year202574 paymentsResearch
    $795,869
  • Eli Lilly
    Program year20255 paymentsResearch
    $277,116
  • Boehringer Ingelheim
    Program year202558 paymentsResearch
    $60,212
All 161 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    32.5%
    Iron, parenteral preparations32.5%
    Ferric carboxymaltose100%
    Part B, office-administered≥13 patients
    P2Y12 inhibitor0%
    Clopidogrel100%
    Part D<11 patients
  • Musculoskeletal

    31.4%
    Other drugs affecting bone structure and mineralization22.8%
    Romosozumab-aqqg100%
    Part B, office-administered≥27 patients
    RANK Ligand Inhibitor7.3%
    Denosumab100%
    Part B, office-administered≥59 patients

    + 2 more classes in this area

  • Cardiovascular

    25.5%
    Other lipid modifying agents22.2%
    Inclisiran100%Icosapent Ethyl0%
    Part D + Part B<11 patients
    Statin1.7%
    Atorvastatin Calcium44%Rosuvastatin Calcium38%Pravastatin Sodium10%Simvastatin8%
    Part D≥121 patients

    + 12 more classes in this area

Where care is delivered (Part B)0.1% facility · 99.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”